Research programme: antibody-drug conjugate therapeutics - Synaffix

Drug Profile

Research programme: antibody-drug conjugate therapeutics - Synaffix

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synaffix
  • Developer Synaffix; Unknown
  • Class Antibodies; Antineoplastics; Drug conjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Nov 2017 Synaffix has patent protection for GlycoConnect™ antibody-drug conjugate technology in Europe
  • 29 Nov 2017 Synaffix plans clinical trials for antibody-drug conjugates containing the company's technology in 2018
  • 16 May 2017 Synaffix has patent protection for HydraSpace™ spacer technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top